

The Silent Killer: Influenza Could Become the Biggest Threat Worldwide

Samiksha S Khobragade*, Rahul G Ingle

Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education & Research (DMIHER), Deemed to be University, Sawangi, Wardha, India.

Received: 18th May, 2024; Revised: 10th July, 2024; Accepted: 01st August, 2024; Available Online: 31st August, 2024

ABSTRACT

Influenza is, commonly called flu, is an acute respiratory illness that is easily communicated and was estimated to affect about 5-15 percent of the adult population in the US alone annually. It is thus important not to underestimate it even if it is seen as just a slight inconvenience that is actually linked to a very dangerous disease that has been taken lightly for too long. To get a perspective of the threat that influenza poses to humanity, it is important to consider the above challenges that are on human health, global climate, and the economy. In this article, an effort will be made to give details of the current scenario of influenza, the possibilities of this disease becoming a pandemic in the future and the steps that are necessary to contain them equally. This article will highlight the mechanisms of mutation and evolution in Influenza virus including antigenic drift and antigenic shift, the current perspective and understanding of antiviral resistance in Influenza viruses, the mechanisms of resistance and impact on treatment outcome

Keywords: Influenza, Pandemic, Resistance, Vaccine.

International Journal of Pharmaceutical Quality Assurance (2024); DOI: 10.25258/ijpqa.15.3.118

How to cite this article: Khobragade SS, Ingle RG. The Silent Killer: Influenza Could Become the Biggest Threat Worldwide. International Journal of Pharmaceutical Quality Assurance. 2024;15(3):1886-1890.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Despite the fact that many pathogens are circulating around the world at the moment, scientists believe that the new pandemic is most likely to be caused by the Flu virus. The perception that flu is the greatest pandemic threat in the world emanates from research conducted in the long-term period that proved that it is a virus that is mutating all the time. Influenza on the other hand is an ailment that is caused by a virus that targets the respiratory tract and manifests symptoms such as fever, cough, sore throat and fatigue. It can easily be transmitted from one person to another via the air when the affected individual is talking, coughing or sneezing. Influenza as estimated by WHO annually, leads to five million incident cases of severe illness; 290,000 to 650,000 deaths.

Rich countries are buying vaccines against H5N1 influenza and increasing vigilance. However, poor countries can be disregarded again. There are continuously new strains of the virus and hence there is no ideal vaccine or treatment for the virus. There are three main types of influenza viruses: A, B and C. Type A and B viruses are known to cause seasonal outbreaks and pandemics, while type C viruses leads to a mild illness. H1N1 and H3N2 are some of the pandemics that are caused by influenza A virus that affects people. The two key genotypic changes elaborated here; the antigenic drift and shift make vaccine development and effectiveness a complicated affair.¹⁻³

Despite advances in understanding the biology and epidemiology of influenza, challenges remain in effectively preventing and treating the disease. Continued research is required to come up with improved vaccines and there are ongoing works toward the universal flu vaccine which will have a broader and longer protection against all the flu strains. Collaboration among governments, academia, and industry will be vital in addressing the ongoing threat of influenza and improving public health outcomes.⁴ Influenza viruses are notorious for their ability to rapidly mutate and evolve, leading to significant challenges in public health, particularly in vaccine development. This review article focuses on the mechanisms of mutation and evolution in influenza viruses, specifically antigenic drift and antigenic shift, which are critical for understanding the virus's adaptability and the implications for vaccine efficacy.

The Potential Challenges for Pandemics

Influenza has the potential to become a global pandemic at any time. The virus is highly contagious and can spread rapidly across the world, especially in areas with poor public health infrastructure and inadequate healthcare systems. A pandemic would not only have devastating consequences for human health but also for economies and societies. Several factors contribute to the risk of an influenza pandemic.

*Author for Correspondence: samiksha.pharmacy@dmher.edu.in

Mutation & Antigenic drift

Antigenic drift on the other hand, is a shift that occurs due to slow mutations that occur in the genetic makeup of the virus, especially in the genes that code for the surface proteins that are the HA and NA. Many of these occur as a direct sequel to point mutations during the process of replication of the virus and lead to slight changes in its antigenicity. Thus, adenoviruses are capable of changing a segment of viral codes to cause the host's immune system to attack a different segment of viral codes when using previous infections or vaccinations. Infected with genes having highly variable mutation rates, which is approximately 10-3 substitutions per site per year is the influenza virus. This is one of the mechanisms that make it possible for the virus to hide from the body's immune response and also the reason why there is need to develop new one flu vaccines every year. Previous research has also demonstrated that dramatic changes in antigenic sites, usually cause the generation of new viral variant that leads to seasonal epidemics.^{5,6}

Antigenic Shift

As to the changes in flu virus, there is the currently less frequently happening antigenic shift which is a more significant process by which two different strains of the virus infect the same host cell and interchange their genetic material. This process of reassortment can bring a new HA or NA protein which is the cause of a new pandemic. Antigenic drift is more common in influenza A viruses and these viruses can infect birds, pigs and humans, making it easier for the genes of the different subtypes to be combined. The possible occurrence of an antigenic shift is a problem for public health because it is a process that may result in the appearance of a virus new to human beings and against which human society does not possess immunity. Examples of historical pandemics include the 2009 H1N1 outbreak that exhibits the effects of an antigenic shift to justify the constant monitoring of the Influenza virus among humans and other animals.⁷

Due to the constant changes in the influenza virus through the processes of antigenic drift and shift, the development of vaccines becomes a big problem. Their formulations need to be changed every year to cover all the commonly occurring strains. Besides, other approaches, including the computational one created to predict the virus evolution, are crucial to identify potential candidate vaccine strains based on mutation fitness and population seropositivity.⁸ Besides, it is important to realize how mutation comes into play as well as how the immune system reacts to it. In a study, it is found out that although mutation may provide the organism with elements of immunity, it may also be a disadvantage. The outcome of these two forces determines the evolution of the virus and therefore, vaccination should embrace both the genetic and the antigenic forces.⁹

Antiviral Resistance

Influenza viruses are known for their ability to rapidly evolve and develop resistance to antiviral drugs, posing significant

challenges in managing and controlling influenza outbreaks. he two main classes of influenza antivirals are the M2 inhibitors (adamantanes) and the neuraminidase inhibitors (NAIs).

More than 99% of the AUM isolates tested in this study exhibit resistance to M2 inhibitors amantadine and rimantadine because of a mutation in the M2 protein at the 31st amino acid substituted by asparagine. This resistance started developing in influenza A H3N2 viruses in 2003 and by 2008 it had reached its peak. The pandemic 2009 influenza A H1N1 virus also come with the S31N mutation, readily contributing to adamantane resistance that exists in circulating H1N1 today. Erythema infectiosum is resistant mainly to NAIs such as oseltamivir and zanamivir and is linked to a mutation of the NA protein. H275Y in the NA of influenza A H1N1 viruses appeared in 2007 and were the predominant circulating strains in 2008–09 season. But the oseltamivir-resistant seasonal H1N1 virus was replaced by the oseltamivir-sensitive pandemic H1N1 virus in the year 2009.¹⁰ It has also been noted that resistance to NAIs is well-pronounced in immunocompromised patients and children because of increased viral load and relatively longer treatment periods. Nevertheless, the clinical significance of resistance is occasionally uncertain since the resistant viruses may or may not offer biological advantages or result in more severe disease.¹¹ To decrease the effects of antiviral resistance, several practices include: the appropriate use of antivirals, using more than one antiviral, coming up with new antivirals, and increasing the strength of public health interventions.

Global connectivity

The increasing ease of international travel and trade means that infected individuals can spread the virus rapidly across the globe.

Lack of immunity

The majority of people are not immune to new strains of influenza, making them susceptible to infection.

Health Consequences of a Pandemic

Influenza pandemics can overwhelm healthcare systems, leading to a cascade of health-related issues:

Increased morbidity and mortality

The 1918 pandemic saw unprecedented death rates, with life expectancy dropping significantly due to the high number of fatalities. Subsequent pandemics, such as those in 1957 and 1968, while less deadly, still caused substantial mortality, particularly among vulnerable populations.¹²

Strain on healthcare resources

Pandemics often result in a surge of patients, overwhelming hospitals and healthcare providers. For instance, during the 1918 pandemic, healthcare facilities were rapidly filled, leading to inadequate care for both influenza patients and those with other medical needs. This strain can result in increased mortality from non-influenza-related conditions due to lack of access to care.¹³

Long-term health effects

Survivors of severe influenza infections may experience long-term health complications, including respiratory issues and decreased overall health status, which can persist for years after the pandemic.¹⁴

Social Consequences of a Pandemic

The social ramifications of influenza pandemics are equally significant:

Public health responses

Pandemics often lead to changes in public health policies and practices, including increased surveillance, vaccination campaigns, and health education initiatives. The lessons learned from past pandemics have informed current preparedness strategies, emphasizing the importance of rapid response and global collaboration.¹⁵

Social disparities

Influenza pandemics disproportionately affect marginalized communities, exacerbating existing health inequalities. Those in lower socioeconomic groups often have less access to healthcare and preventive measures, resulting in higher mortality rates in these populations.¹⁶

Psychosocial effects

The fear and uncertainty surrounding pandemics can lead to increased anxiety and mental health issues among the population. The societal impact of loss and grief can have lasting effects on community cohesion and individual well-being.¹⁷

Economic consequences of a pandemic

The economic impact of influenza pandemics is profound and multifaceted:

Direct costs

These include healthcare expenditures for treatment and vaccination programs. The 2009 H1N1 pandemic, for example, incurred costs estimated at \$60 billion annually, highlighting the financial burden associated with pandemic preparedness and response.¹⁸

Indirect costs

Pandemics disrupt economies through loss of productivity, increased absenteeism, and changes in consumer behavior. Businesses may face closures or reduced operations due to illness among staff, leading to economic downturns in affected regions.¹⁹

Global economic impact

The interconnectedness of global economies means that an influenza pandemic can have far-reaching effects, disrupting supply chains and international trade, as seen during the COVID-19 pandemic.^{20,21}

The Impact on Global Health

Influenza is a highly contagious and potentially deadly disease. According to the WHO, seasonal influenza outbreaks result in

an estimated 3-5 million cases of severe illness and 290,000-645,000 deaths worldwide each year. These numbers are likely underestimates, as many cases go unreported or misdiagnosed.

The global health implications of influenza are significant. In areas with weak healthcare systems, outbreaks can quickly spread and overwhelm healthcare infrastructure, leading to devastating consequences.

Mitigating the Threat

While the threat of influenza is real, there are several measures that can be taken to mitigate its impact.

Vaccination

Vaccination is the most effective way to prevent influenza. Developing effective vaccines against emerging strains is crucial.

Surveillance

Monitoring the virus's evolution and spread can help identify potential outbreaks early on.

Public health infrastructure

Strengthening public health infrastructure in countries with inadequate resources can help prevent and respond to outbreaks.

Global cooperation

International cooperation and coordination are essential for responding to pandemics effectively.

Research

Continued research into influenza virology, immunology, and treatment options is vital for developing effective strategies against the virus.

The Rise of Antiviral Resistance

One of the primary concerns surrounding influenza is the emergence of antiviral resistance. Overuse and misuse of antiviral medications have led to the development of resistant strains, making them ineffective against certain types of influenza. This is particularly problematic in areas where healthcare resources are limited, making it difficult for patients to access effective treatment.

In 2019, the WHO reported that 70% of all flu cases worldwide were resistant to oseltamivir, a commonly used antiviral medication. This trend has been linked to the overuse of antivirals in developed countries, which has contributed to the development of resistance in circulating strains.

The Economic Burden

Influenza also poses a significant economic burden on individuals and communities worldwide. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that influenza costs the economy around \$10 billion annually in lost productivity and healthcare costs.

Globally, the economic impact of influenza is likely to be even more substantial. In areas with limited economic resources, outbreaks can have devastating effects on local economies, exacerbating poverty and social inequality.

The Need for Urgent Action²²⁻²⁵

The increasing threat posed by influenza demands urgent action from governments, healthcare organizations, and individuals worldwide. To mitigate this threat, several measures must be taken:

Improved vaccine development

New vaccine technologies are needed to combat emerging strains of influenza and improve global vaccine distribution.

Enhanced antiviral resistance monitoring

Regular surveillance is necessary to track the emergence of resistant strains and develop effective treatment strategies.

Improved healthcare infrastructure

Weak healthcare systems must be strengthened to ensure timely diagnosis and treatment of influenza cases.

Public awareness and education

Individuals must be educated about the risks and consequences of influenza, promoting responsible behavior and encouraging vaccination.

Global collaboration

International cooperation is essential to share knowledge, resources, and best practices in addressing the global threat posed by influenza

CONCLUSION

Influenza is a significant threat to global health security, with the potential to become a global pandemic at any time. The past of influenza recommends that the virus is extremely unpredictable in its ability to jump species barriers and cause threatening circumstances for mankind. Influenza virus evolution through mutation and reassortment is a complex process that significantly impacts public health. Antigenic drift and shift enable the virus to evade immune responses, complicating vaccine efficacy and necessitating ongoing surveillance and research. As new technologies and models emerge, they provide valuable tools for predicting viral evolution and improving vaccine strategies, ultimately aiming to mitigate the impact of influenza on global health. Continuous efforts in understanding these mechanisms are essential for preparing for future influenza outbreaks and potential pandemics. The consequences of a pandemic would be devastating, causing widespread illness and death, economic disruption, social unrest, and long-term health effects. Antiviral resistance in influenza viruses remains a significant challenge in the management and control of influenza outbreaks. Understanding the mechanisms of resistance, monitoring its impact, and implementing mitigation strategies are essential to ensure the continued effectiveness of antiviral drugs. Influenza pandemics pose significant challenges that extend beyond immediate health impacts. The historical analysis of the 1918 pandemic and subsequent outbreaks reveals a pattern of severe health, economic, and social consequences. Preparedness efforts must continue to evolve, leveraging past experiences to mitigate the effects of future pandemics. To mitigate this

threat, it's essential to prioritize vaccination, surveillance, public health infrastructure strengthening, global cooperation, and research into influenza virology and treatment options. Health authorities across the world need to keep influenza preparedness plans that are based on combined surveillance data received. By taking these actions proactively, we can reduce the risk of an influenza pandemic and protect humanity from this silent killer.

ACKNOWLEDGMENTS

The authors are thankful to the Datta Meghe Institute of Higher Education and Research, Wardha, for their financial support.

REFERENCES

- McKie R. Next pandemic likely to be caused by flu virus, scientists warn. *The Observer* Epidemics. 2024.
- World Health Organization. Influenza (Seasonal). Centers for Disease Control and Prevention 2020.
- Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, Simmerman JM, Gordon A, Sato M, Howie S, Krishnan A. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. *The Lancet*. 2011;378(9807):1917-1930.
- Influenza (Flu). National Institute of Allergy and Infectious Diseases. Influenza. 2020.
- Petrova VN, Russell CA. The evolution of seasonal influenza viruses. *Nature Reviews Microbiology*. 2018;16(1):47-60. <https://doi.org/10.1038/nrmicro.2017.118>
- Wille M, Holmes EC. The ecology and evolution of influenza viruses. *Cold Spring Harbor perspectives in medicine*. 2020;10(7):a038489. <https://doi.org/10.1101/2020.07.10.38489>
- Treanor J. Influenza vaccine—outmaneuvering antigenic shift and drift. *New England Journal of Medicine*. 2004;350(3):218-220.
- Lou J, Liang W, Cao L, Hu I, Zhao S, Chen Z, Chan RW, Cheung PP, Zheng H, Liu C, Li Q. Predictive evolutionary modelling for influenza virus by site-based dynamics of mutations. *Nature communications*. 2024;15(1):2546.
- Xue KS, Bloom JD. Linking influenza virus evolution within and between human hosts. *Virus evolution*. 2020;6(1):veaa010. <https://doi.org/10.1093/ve/veaa010>
- Krammer F, Smith G.J.D., Fouchier R.A.M. *et al*. Influenza. *Nature Reviews Disease Primers*, 3 (2018). <https://doi.org/10.1038/s41572-018-0002-y>
- Holmes EC, Hurt AC, Dobbie Z, Clinch B, Oxford JS, Piedra PA. Understanding the impact of resistance to influenza antivirals. *Clinical Microbiology Reviews*. 2021;34(2):10-128.
- Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. *The Journal of infectious diseases*. 2007;195(7):1018-1028. <https://doi.org/10.1086/511989>
- Lemon SM, Mahmoud AA. The threat of pandemic influenza: are we ready? *Biosecurity and bioterrorism: biodefense strategy, practice, and science*. 2005;3(1):70-73.
- Mallapaty S. Bird flu could become a human pandemic. How are countries preparing? *Nature*. 2024.
- Paget J. The influenza pandemic and Europe: the social impact and public health response.
- Blumenshine P, Reingold A, Egerter S, Mockenhaupt R,

- Braveman P, Marks J. Pandemic influenza planning in the United States from a health disparities perspective. *Emerging infectious diseases*. 2008;14(5):709. <https://doi.org/10.3201%2Fid1405.071301>
17. Barello S, Falcó-Pegueroles A, Rosa D, Tolotti A, Graffigna G, Bonetti L. The psychosocial impact of flu influenza pandemics on healthcare workers and lessons learnt for the COVID-19 emergency: a rapid review. *International journal of public health*. 2020 Sep;65(7):1205-1216. <https://doi.org/10.1007%2Fs00038-020-01463-7>
 18. Szucs T. The socioeconomic burden of influenza. *Journal of Antimicrobial Chemotherapy*. 1999 Nov 1;44(suppl_2):11-15.
 19. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. *Emerging infectious diseases*. 1999;5(5):659. <https://doi.org/10.3201%2Fid0505.990507>
 20. Ajmal MM, Khan M, Shad MK. The global economic cost of coronavirus pandemic: current and future implications. *Public Administration and Policy*. 2021;24(3):290-305. <https://doi.org/10.1108/PAP-10-2021-0054>
 21. Kumar B, Kumari A, Khanna M. The emerging influenza virus threat: status and new prospects for its therapy and control. *Archives of Virology*. 2018; 163(4): 831–844. doi: 10.1007/s00705-018-3708-y.
 22. Zayer JAR, Chiad IA. Evaluation of Application of Effective vaccine management in Wassit Governorate, Iraq. *International Journal of Pharmaceutical Quality Assurance*. 2020;11(2):242-246. DOI: 10.25258/ijpqa.11.2.9
 23. Santha KK, Mohan S, Prasada RK. Method Development and Validation for Famciclovir and Valacyclovir by using UPLC and its Degradents are Characterized by LC-MS/MS. *International Journal of Pharmaceutical Quality Assurance*. 2022;13(3):232-239. DOI: 10.25258/ijpqa.13.3.02
 24. Hasan HT, Kadhim EJ. Phytochemical Investigation and Pharmacological Activity of *Solidago canadensis* L. against H1N1 Virus, involving the Separation and Identification of Three New Compounds. *International Journal of Drug Delivery Technology*. 2023;13(1):180-192. DOI: 10.25258/ijddt.13.1.28
 25. Jameel YM, Nasir RS. Genetic sequence of drug-resistant *Haemophilus influenzae* isolated from respiratory tract infections. *International Journal of Drug Delivery Technology*. 2020;10(2):307-310. DOI: 10.25258/ijddt.10.2.20